Liver preference has been proposed as a key mechanism that underlies the lower hypoglycemia risk associated with physiological insulin, which subcutaneously delivered insulins generally lack and contributes to their elevated hypoglycemia risk compared to endogenous insulin [32–34]. The gene discussed is INS; the disease is Hypoglycemia.